Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Healthcare Sector Analysis

UpdatedSep 12, 2025
DataAggregated Company Financials
Companies35
  • 7D-1.9%
  • 3M1.9%
  • 1Y2.0%
  • YTD7.0%

Over the last 7 days, the Healthcare industry has dropped 1.9%, driven by a pullback from Roche Holding of 2.6%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 14% annually.

Sector Valuation and Performance

Has the Swiss Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 13 Sep 2025CHF 618.9bCHF 153.5bCHF 24.1b32.4x25.6x4x
Mon, 11 Aug 2025CHF 583.6bCHF 154.2bCHF 24.3b29.3x24x3.8x
Wed, 09 Jul 2025CHF 587.7bCHF 149.7bCHF 22.2b30.3x26.5x3.9x
Fri, 06 Jun 2025CHF 593.5bCHF 151.6bCHF 22.6b30.5x26.3x3.9x
Sun, 04 May 2025CHF 591.4bCHF 151.8bCHF 22.5b31x26.2x3.9x
Tue, 01 Apr 2025CHF 601.5bCHF 155.0bCHF 22.5b29.6x26.7x3.9x
Thu, 27 Feb 2025CHF 632.1bCHF 155.2bCHF 22.3b26.5x28.3x4.1x
Sat, 25 Jan 2025CHF 604.1bCHF 152.6bCHF 24.5b31.1x24.6x4x
Mon, 23 Dec 2024CHF 556.2bCHF 151.7bCHF 24.4b28.1x22.8x3.7x
Wed, 20 Nov 2024CHF 566.5bCHF 150.9bCHF 24.3b28.1x23.3x3.8x
Fri, 18 Oct 2024CHF 616.5bCHF 148.6bCHF 22.6b31x27.3x4.1x
Sun, 15 Sep 2024CHF 604.8bCHF 147.2bCHF 22.3b32.8x27.1x4.1x
Tue, 13 Aug 2024CHF 604.7bCHF 148.1bCHF 22.3b29.6x27.1x4.1x
Thu, 11 Jul 2024CHF 584.3bCHF 149.1bCHF 22.7b37.6x25.7x3.9x
Sat, 08 Jun 2024CHF 572.5bCHF 148.9bCHF 22.7b35.4x25.2x3.8x
Mon, 06 May 2024CHF 528.8bCHF 145.7bCHF 22.8b32.8x23.2x3.6x
Wed, 03 Apr 2024CHF 548.4bCHF 144.8bCHF 22.3b36.1x24.6x3.8x
Fri, 01 Mar 2024CHF 527.5bCHF 143.3bCHF 22.7b35.8x23.3x3.7x
Sun, 28 Jan 2024CHF 546.3bCHF 152.6bCHF 21.4b34x25.5x3.6x
Tue, 26 Dec 2023CHF 522.8bCHF 151.6bCHF 21.8b26.3x24x3.4x
Thu, 23 Nov 2023CHF 513.5bCHF 153.9bCHF 22.1b24.5x23.2x3.3x
Sat, 21 Oct 2023CHF 505.6bCHF 153.2bCHF 21.6b25.7x23.4x3.3x
Mon, 18 Sep 2023CHF 551.7bCHF 145.0bCHF 21.1b35.4x26.1x3.8x
Wed, 16 Aug 2023CHF 548.9bCHF 143.5bCHF 21.1b32.1x26x3.8x
Fri, 14 Jul 2023CHF 548.3bCHF 144.9bCHF 22.0b36.3x25x3.8x
Sun, 11 Jun 2023CHF 573.1bCHF 147.6bCHF 22.3b34.4x25.7x3.9x
Tue, 09 May 2023CHF 586.9bCHF 146.6bCHF 22.3b33.4x26.3x4x
Thu, 06 Apr 2023CHF 564.5bCHF 147.3bCHF 22.4b32.6x25.2x3.8x
Sat, 04 Mar 2023CHF 541.3bCHF 148.9bCHF 22.6b35.8x24x3.6x
Mon, 30 Jan 2023CHF 583.3bCHF 149.7bCHF 38.6b31.4x15.1x3.9x
Wed, 28 Dec 2022CHF 561.5bCHF 148.8bCHF 38.1b29.4x14.7x3.8x
Fri, 25 Nov 2022CHF 577.0bCHF 149.6bCHF 38.5b34.2x15x3.9x
Sun, 23 Oct 2022CHF 569.2bCHF 153.5bCHF 40.9b26.2x13.9x3.7x
Tue, 20 Sep 2022CHF 569.1bCHF 151.1bCHF 39.9b28.3x14.3x3.8x
Price to Earnings Ratio

14.3x


Total Market Cap: CHF 569.1bTotal Earnings: CHF 39.9bTotal Revenue: CHF 151.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Healthcare Sector Price to Earnings3Y Average 23.8x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 23.8x.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 15% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare sector?

CH Market-0.29%
Healthcare-1.85%
Medical Equipment-0.61%
Healthcare Services-1.32%
Pharma-1.92%
Life Sciences-2.80%
Biotech-3.81%
Healthtech-8.26%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 23.5x.
    • Analysts are expecting annual earnings growth of 40.4%, which is higher than its past year's earnings decline of 80.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 40% over the next 5 years.
  • This is better than its past earnings decline of 80% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 4.9% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GALD Galderma GroupCHF 145.800.8%
+CHF 261.1m		84.6%PE115x
DESN Dottikon ES HoldingCHF 304.004.3%
+CHF 172.7m		25.1%PE39.8x
MOVE Medacta GroupCHF 150.605.8%
+CHF 163.5m		20.7%PE33.9x
IDIA IdorsiaCHF 3.6225.5%
+CHF 153.8m		119.8%PS3.5x
YPSN Ypsomed HoldingCHF 410.002.0%
+CHF 109.2m		-3.1%PE63.9x

Latest News

MOVE
CHF 150.60
Medacta Group
7D
5.8%
1Y
20.7%

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?

Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?
GALD
CHF 145.80
Galderma Group
7D
0.8%
1Y
84.6%
SFZN
CHF 86.30
Siegfried Holding
7D
1.5%
1Y
-26.6%

Pharmaceutical Outsourcing And Supply Chain Resilience Will Drive Future Expansion

Siegfried Holding’s consensus analyst price target saw a marginal decrease to CHF110.67, as both revenue growth forecasts and discount rate assumptions remained effectively unchanged. What's in the News Siegfried Holding expects sales growth in the mid-single-digit percentage range in local currencies for 2025.
LONN
CHF 547.60
Lonza Group
7D
-5.2%
1Y
-1.3%

What Is Lonza Group AG's (VTX:LONN) Share Price Doing?

Sep 10
What Is Lonza Group AG's (VTX:LONN) Share Price Doing?
NOVN
CHF 98.85
Novartis
7D
-4.9%
1Y
0.7%
IDIA
CHF 3.62
Idorsia
7D
25.5%
1Y
119.8%

Global Expansion And FDA Review Will Moderate Overvaluation

Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.
ALC
CHF 62.66
Alcon
7D
-2.2%
1Y
-24.8%
ROG
CHF 264.50
Roche Holding
7D
-3.5%
1Y
-0.4%
YPSN
CHF 410.00
Ypsomed Holding
7D
2.0%
1Y
-3.1%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

Ypsomed Holding’s analyst price target has been revised upward to CHF463.26 as the company consolidates its leadership in the high-growth injectables market following strategic divestitures and a sharpened operational focus. Analyst Commentary The company has established a leadership position in the high-growth injectable market.
STMN
CHF 92.00
Straumann Holding
7D
-3.1%
1Y
-25.4%

Asia-Pacific And Latin America Will Transform Digital Dentistry

Straumann Holding’s consensus price target was reiterated at CHF117.00 as analysts balanced concerns about margin pressure, slower growth, and macroeconomic risks with confidence in the company’s long-term strategy and innovation. Analyst Commentary Bearish analysts cite ongoing margin pressure and weaker-than-expected profitability as headwinds for Straumann.
COPN
CHF 67.60
Cosmo Pharmaceuticals
7D
3.0%
1Y
-14.4%

Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges

Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.
SOON
CHF 237.90
Sonova Holding
7D
-0.7%
1Y
-21.7%
SANN
CHF 14.78
Santhera Pharmaceuticals Holding
7D
3.8%
1Y
61.7%
SDZ
CHF 47.86
Sandoz Group
7D
-2.1%
1Y
35.9%

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
BANB
CHF 61.45
Bachem Holding
7D
-3.4%
1Y
-18.8%

Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
DESN
CHF 304.00
Dottikon ES Holding
7D
4.3%
1Y
25.1%

Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?

Aug 13
Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?